Avidity Biosciences stock leaves Nasdaq after Novartis deal

Avidity Biosciences stock left Nasdaq after Novartis completed its acquisition on February 27, 2026. The transaction offered USD 72.00 per share and valued the former biotech at roughly USD 12 billion, according to Peptide and Protein.

USD 72.00 offer ended RNA trading

The cash offer represented a 46 percent premium to Avidity's October 24, 2025 closing price, according to the same report. That comparison explains why the transaction became the decisive event for holders of the former RNA listing rather than a routine change in ownership.

The acquisition also changed the status of Avidity's public equity. The report says the merger closed on February 27, 2026, ending Avidity's run on Nasdaq and transferring its pipeline into Novartis.

Pipeline value moved to Novartis

Avidity developed antibody oligonucleotide conjugates, or AOCs, combining monoclonal antibodies with oligonucleotides. Its investor relations page describes the platform as a targeted RNA therapeutic approach designed to reach tissue and cell types that were previously difficult to access.

The former company's lead clinical asset was del-desiran, a treatment for myotonic dystrophy type 1. On September 8, 2026, the Phase III HARBOR trial missed its primary endpoint, with the result adding a new test to the value Novartis must extract from the acquisition, according to Fierce Biotech.

Former RNA listing has changed

For investors reviewing historical Avidity Biosciences data, the key figures are the USD 72.00 offer price, the roughly USD 12 billion transaction value and the February 27, 2026 closing date. Those figures describe a completed takeover, not a current Nasdaq quote for Avidity.

The distinction matters because the RNA symbol can now refer to a different listed company in live market databases. Avidity's corporate platform remains centered on AOC research, while ownership of its development programs sits with Novartis after the completed transaction.